In it, they give the example of a cancer drug called nivolumab, which can improve outcomes for patients. In trials – during which people with different 'types' of cancer were included – the drug has ...

The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.

Sep. 27, 2024 — Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study unexpectedly finds that estrogens play a role in fueling the growth of ...

The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached ...

The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.

If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...

A phase 2 trial investigated the efficacy and safety of nivolumab/ipilimumab in molecularly selected patients with mCRPC, including those with a mismatch repair deficient, high tumor mutational burden ...

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...